Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1476205
This article is part of the Research Topic Treatment of Brain Metastases from Non-Small Cell Lung Cancer: Preclinical, Clinical, and Translational Research View all 14 articles

Penpulimab and Anlotinib in PD-L1 High-Expression Pulmonary Giant Cell Carcinoma with Cerebral Metastases: Case Report and Review

Provisionally accepted
Minghong Xie Minghong Xie Liu Haiwei Liu Haiwei Xiaohua Hou Xiaohua Hou Haiwei Liu Haiwei Liu Ning Li Ning Li Sha Niu Sha Niu Xinju Xu Xinju Xu *
  • Second People's Hospital of Jiaozuo City, Jiaozuo, China

The final, formatted version of the article will be published soon.

    Pulmonary giant cell carcinoma (PGCC) is a rare subtype of non-small cell lung cancer (NSCLC) characterized by complex pathology, high rates of misdiagnosis or missed diagnosis, an aggressive clinical course, rapid progression, and poor prognosis. This case report describes a 67-year-old Chinese male with a left upper lobe lung mass, diagnosed via CT-guided lung biopsy as PGCC with symptomatic multiple cerebral metastases.The tumor showed strong PD-L1 positivity, and genetic testing revealed a TP53 exon 4 c.313G mutation. Treatment involved first-line therapy with Penpulimab injection combined with Anlotinib and concurrent cranial radiotherapy. Significant reduction in both the pulmonary and cerebral metastatic lesions was observed, with notable efficacy. As of June 2024, there has been no disease progression for 26 months, with the patient currently maintained on Anlotinib monotherapy. This case demonstrates the favorable efficacy of Penpulimab injection combined with Anlotinib in treating advanced PGCC. These findings indicate that this combination 2 therapy may offer a promising new therapeutic option for this rare type of lung cancer.

    Keywords: pulmonary giant cell carcinoma, Penpulimab injection, Anlotinib, Cerebral metastases, PD-L1 positivity

    Received: 05 Aug 2024; Accepted: 04 Dec 2024.

    Copyright: © 2024 Xie, Haiwei, Hou, Liu, Li, Niu and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xinju Xu, Second People's Hospital of Jiaozuo City, Jiaozuo, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.